CareDx, Inc. CDNA
Regular-session close
Pre-market · Nov 20, 4:57 AM ET
- YTD
- +281.74%
- 1 year
- +350.06%
5D -5.81 (-7.43%)
- Market cap
- 3.78B
- Revenue (ttm)
- 497.40M
- Profit margin
- 25.86%
- EPS (ttm)
- 2.37
- Shares out
- 52.54M
- P/E ratio
- 30.35
- Forward P/E
- 45.98
- YTD return
- +281.74%
- 1-year return
- +350.06%
- 50-day average
- 67.77
- Volume
- 878.35K
- Avg volume
- 1.31M
- Open
- 74.56
- Previous close
- 74.44
- Day's range
- 71.59 – 76.90
- 52-week range
- 15.56 – 90.87
- Beta
- 2.49
- Analysts
- Buy
- Price target
- 94.43 (+31.3%)
- Earnings date
- Feb 23, 2027
Key statistics
- 200-day average
- 37.51
- Enterprise value
- 3.69B
- Price / sales
- 7.60
- Price / book
- 8.07
- Revenue growth
- 39.30%
- Free cash flow
- 130.45M
- Total cash
- 250.48M
- Total debt
- 29.00M
- Return on equity
- 33.04%
- Short % of float
- 13.93%
Fundamental scorecard
11 of 25 checks passed on CDNA’s reported financials
11of 25 checks passed
- Value 0 of 5
- Growth 3 of 5
- Profitability 3 of 5
- Financial health 5 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Analyst view
Consensus: buy
- Target (low)
- 90.00
- Target (mean)
- 94.43
- Target (high)
- 100.00
- Strong buy1
- Buy5
- Hold2
- Sell0
- Strong sell0
Next earnings
Feb 23, 2027
Expected Feb 23, 2027. Consensus EPS estimate 0.36.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 23, 2027 | Dec 30, 2026 | 0.33 | — | — | — |
| Oct 29, 2026 | Sep 30, 2026 | 0.2548 | 0.70 | +0.45 | +174.73% |
| Jul 30, 2026 | Jun 30, 2026 | 0.2321 | 0.37 | +0.14 | +59.41% |
| Apr 28, 2026 | Mar 31, 2026 | 0.11 | 0.34 | +0.23 | +209.09% |
| Feb 24, 2026 | Dec 31, 2025 | 0.0199 | 0.12 | +0.10 | +503.02% |
| Nov 4, 2025 | Sep 30, 2025 | -0.08192 | 0.0319 | +0.11 | +138.94% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 11, 2026 | Piper Sandler | init | — | Overweight |
| Oct 30, 2026 | BTIG | main | Buy | Buy |
| Oct 27, 2026 | BTIG | main | Buy | Buy |
| Oct 19, 2026 | Canaccord Genuity | main | Buy | Buy |
| Sep 24, 2026 | BTIG | main | Buy | Buy |
| Sep 2, 2026 | Canaccord Genuity | init | — | Buy |
About CareDx, Inc.
CareDx, Inc. provides solutions for improving outcomes for transplant patients and advancing organ health in the United States and internationally. The company provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression profiling solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. It also offers HeartCare, which provides information about distinct biological processes, such as immune quiescence, active injury, acute cellular rejection, and antibody mediated rejection; HistoMap Kidney, a solution that identifies allograft rejection and type of rejection in kidney transplant biopsy tissue; and AlloHeme, a monitoring test that predicts relapse in patients with acute myeloid leukemia and myelodysplastic syndromes. In addition, the company provides QTYPE that enables precision in human leukocyte antigen (HLA) typing; Olerup SSP, which is used to type HLA alleles based on sequence specific primer technology; and Ottr, a transplant patient management software. Further, it offers AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a solution that monitors the pharmacokinetics of engraftment and persistence of cells for patients who have received allogeneic cell therapy; and XynQAPI, MedActionPlan, CareDx pharmacy, AlloHome, and HLA Data Systems software solutions. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in Brisbane, California.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Country
- United States
- Website
- caredx.com
News
CytomX Therapeutics (NASDAQ:CTMX) and CareDx (NASDAQ:CDNA) Critical Analysis
Wall Street Analysts Think CareDx (CDNA) Could Surge 28.09%: Read This Before Placing a Bet
This Zebra Technologies Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday Piper Sandler Initiates Coverage On CareDx with Overweight Rating, Announces Price Target of $100
12 Health Care Stocks Moving In Friday's Intraday Session
AutoNation, Regeneron Pharmaceuticals, AstraZeneca And Other Big Stocks Moving Higher On Friday
Why Civeo Shares Are Trading Higher By 20%; Here Are 20 Stocks Moving Premarket
12 Health Care Stocks Moving In Thursday's After-Market Session CareDx Raises FY2026 Sales Guidance from $490.000M-$500.000M to $520.000M-$530.000M vs $489.692M Est
CareDx Q3 Adj. EPS $0.70 Beats $0.25 Estimate, Sales $139.362M Beat $120.608M Estimate
Your note
Sign in to keep a note on CDNA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BICKERSTAFF GEORGE W III | Director | Sale | Aug 4, 2026 | 134,061 |
| COHEN FREDERICK E. M.D. PH.D. | Director | Stock Gift | Nov 2, 2026 | 140,060 |
| HAGSTROM WILLIAM A | Director | Sale | Jun 10, 2025 | 53,979 |
| HANNA JOHN WALTER JR | Chief Executive Officer | Sale | Jul 15, 2026 | 653,448 |
| JAIN ABHISHEK | Chief Financial Officer | Sale | Apr 6, 2025 | 337,418 |
| KENNEDY KEITH S | Chief Operating Officer | Sale | Nov 11, 2026 | 199,147 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 9.27% | 4,871,787 | 350.38M | Sep 29, 2026 |
| State Street Corporation | 4.99% | 2,623,064 | 188.65M | Sep 29, 2026 |
| Vanguard Capital Management LLC | 4.17% | 2,193,550 | 157.76M | Sep 29, 2026 |
| Arrowstreet Capital, Limited Partnership | 3.92% | 2,059,397 | 148.11M | Sep 29, 2026 |
| Blue Water Life Science Advisors, Lp | 3.31% | 1,740,000 | 125.14M | Sep 29, 2026 |
| ARK Investment Management, LLC | 3.06% | 1,609,054 | 115.72M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.96% | 1,554,868 | 111.83M | Jun 29, 2026 |
| BARON INVESTMENT Fd.S TRT -BARON DISCOVERY Fd. | 2.61% | 1,373,550 | 98.79M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.53% | 1,329,541 | 95.62M | Sep 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.51% | 1,321,241 | 95.02M | Sep 29, 2026 |
| ARK ETF Trust-ARK Genomic Revolution ETF | 2.11% | 1,109,821 | 79.82M | Oct 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 1.12% | 588,494 | 42.32M | Jun 29, 2026 |
